Summary of Key Points
Connaughtia utilized the “NewCo model” (partnering with overseas investors to establish a new company and licensing its drugs) to introduce the cancer drug CM336 to international markets. In less than two years, the new company was acquired by Gilead, and Connaughtia received an upfront payment of $257 million, along with additional milestones and sales royalties. This approach allows Connaughtia to earn licensing fees while also benefiting from the appreciation in the value of its equity in the new company, effectively solving its funding challenges and leveraging overseas resources to advance the drug’s development—a more cost-effective strategy than traditional licensing methods.
Detailed Explanation
1. The NewCo Model: Not Just Licensing, but Partnering in Drug Development
Traditional licensing agreements involve selling the rights to develop or sell a drug abroad for an upfront payment plus milestones and royalties. However, the NewCo model is different: it involves forming a new company with overseas investors (such as Ouro in this case). Connaughtia licenses its drug to the new company while also holding shares in it. This way, when the new company is acquired or goes public, Connaughtia can profit from the increase in its equity value.
For example, if you have a promising formula, instead of just selling it, you could partner with others to open a business using that formula. If the business succeeds and gets acquired, you would not only receive payment for the formula but also a share of the acquisition proceeds.
2. How Much Has Connaughtia Earned So Far? Both Cash and Potential Revenue
- Already Received: $257 million in upfront payments (approximately RMB 1.8 billion) + an initial payment of $16 million, totaling over $270 million (RMB 1.9 billion);
- Future Earnings: Up to $70 million in milestones (e.g., successful clinical trials) + the previously agreed-upon milestone payment of $610 million + sales royalties (to be fulfilled by Gilead).
These funds are a much-needed boost for Connaughtia, which was incurring losses in 2025 (with a loss of RMB 523 million).
3. What Makes the NewCo Model Better Than Traditional Licensing? The Added Value of Equity Appreciation
Traditional licensing only provides a fixed amount of revenue, but with the NewCo model, Connaughtia can benefit from additional profits if the new company is acquired. For instance, when Ouro was acquired by Gilead for $2.175 billion, Connaughtia as a shareholder received an upfront payment of $257 million. It’s like selling a product and also investing in a potentially profitable stock that could appreciate in value. Moreover, the new company’s investors will provide the necessary resources to advance the drug’s development, freeing Connaughtia from bearing the risks associated with overseas research and development.
4. Not Every Company Can Use the NewCo Model: It Requires Financial Strength and Reliable Partners
According to lawyers at MF Partners, this model is complex and not suitable for all pharmaceutical companies:
- Limited Companies May Not Be Suitable: If a company only has one or two core drugs, using the NewCo model could result in the loss of control over those drugs (as the new company takes the lead in their development);
- Reputable Partners Are Essential: Investors must have the necessary resources (such as access to overseas hospitals, clinical teams, and funding) to ensure the new company’s success. Connaughtia clearly identified investors with the required capabilities, which is why Ouro caught Gilead’s attention.
5. Why Did Connaughtia Choose the NewCo Model? Need for Funds and Resources
Although Connaughtia has drugs available for sale in China, it was struggling financially due to high research and development costs. The NewCo model:
- Eliminates the Need for Overseas R&D Expenses: The new company’s investors cover these costs;
- Leverages Overseas Resources: It utilizes overseas hospitals for clinical trials and teams for commercialization, accelerating the process compared to starting from scratch;
- Reduced Risks: Overseas market risks are borne by the new company and its investors, while Connaughtia focuses on providing its technology and securing a stable income stream.
It’s similar to trying to sell a product abroad without the necessary channels or funds—by partnering with foreign entities, they can provide the resources and distribution network, and you can share the profits while sharing the risks.
This model enables Connaughtia to enter international markets more efficiently, addressing its funding issues and leveraging overseas capabilities to accelerate the commercialization of its drugs. It represents a new approach for domestic innovative pharmaceutical companies looking to expand globally. However, it requires having a diverse product portfolio and finding the right investors; otherwise, the company may risk losing control over its core assets.